Zacks Small Cap Research – PLX: Revisiting the Thesis – Go Health Pro
By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Reasons To Own / A Compelling Idea for 2025 Protalix Biotherapeutics, Inc. (NYSE:PLX) finds itself in an enviable position as we begin 2025. The company has two approved products generating revenues and a pipeline with multiple candidates in development. Its products are produced and … Read more
